Corsair Pharma‘s experimental skin patch designed to deliver treprostinil, an approved treatment for pulmonary arterial hypertension (PAH), appears to be working as intended, according to newly announced data from an early clinical trial in healthy volunteers. Several treprostinil formulations are already approved for pulmonary arterial hypertension: subcutaneous 24/7 infusion (Remodulin and generics), oral (Orenitram, not approved in Europe), and inhaled (Tyvaso, also now approved for pulmonary hypertension with interstitial lung disease (PH-ILD). These are all sold by United Therapeutics, which is collaborating with Corsair on the patch. Liquidia also markets an inhaled version of treprostinil, Yutrepia, for pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease.
Read more at this link on Pulmonary Hypertension News